Tristel plc

TSTL.L · Healthcare · Medical Instruments & Supplies · Valued as of 2026-11-03 · Statements 2025-06-30

How Each Value Is Built

The screener's three formulas on the reported figures. Each card reads the same way: the value as a sum of numbered terms, each term's calculation opened under it, from the reported figures to the value. The list ranks companies by their plain average over the market cap.

What it is worth

EPV + Growth

179.79M USD

what the normal year's earnings are worth for ever, plus growth that pays

Profit

123.03M USD

15 years of cash the shareholders can take out, and the equity left at year 15

FCFF

117.34M USD

15 years of cash for shareholders and lenders, less what is owed

Average Intrinsic Value

140.06M USD

The plain average of EPV, Profit and FCFF

Against the price

Market Cap

265.44M USD

the price on the date above times the shares

Intrinsic Value ÷ Market Cap

0.53×

the ratio the screener ranks by

Margin of Safety

-89.5%

1 − Market Cap / Average Intrinsic Value

Projections, not exact values. Intrinsic Values are projected from each company's past reports. They show which stocks look cheap compared with the others, not exactly what a stock is worth.

Earnings power value plus growth: 179.79M USD
What the normal year's operating profit after tax is worth if it lasts for ever, plus what the new investment adds beyond its cost, less the net debt that comes before the shareholders (or plus the net cash).
①EPV (earnings power value)114.57M USD
+②Net Cash Today10.06M USD
+③Growth Value55.16M USD
=Value179.79M USD

EPV of the Operations (NOPAT over WACC)

114.57M USD

Net cash today

+10.06M USD

Growth Value

+55.16M USD

Value

179.79M USD

①EPV (earnings power value)

114.57M USD

②Net Cash Today

10.06M USD

③Growth Value

55.16M USD

Market value

Market Cap265.44M USD

The price on the date above times the shares.

Value vs market

Margin of Safety-47.6%

1 minus the market cap as a share of the value.

Profit value: today's value of the shareholders' equity, from the cash it can pay them (FCFE): 123.03M USD
Fifteen years of free cash flow to equity (FCFE), each brought to today at the cost of equity, plus the equity at year 15 brought to today.
①Present Value of the 15 Years of FCFE91.28M USD
+②Equity at Year 15, Today31.75M USD
=Value123.03M USD
FCFE: the net income left for the shareholders once the business keeps what next year's growth needsEquity reinvestment: the part of the year's net income kept in the business to grow the next year; below zero, capital the business releases to the shareholdersPresent value of the FCFEColoured bars show the FCFE, grey bars the equity reinvestment. With a positive equity reinvestment the two stacked are the year's normalized income; with a negative one the grey is below zero, capital the business releases, and the normalized income is the FCFE plus that negative amount. Shaded, years 6 to 10: the growth rising to its long-run rate and the ROE on new investment falling to the cost of equity. Axes linear.

①Present Value of the 15 Years of FCFE

91.28M USD

②Equity at Year 15, Today

31.75M USD

Market value

Market Cap265.44M USD

The price on the date above times the shares.

Value vs market

Margin of Safety-115.8%

1 minus the market cap as a share of the value.

FCFF value: today's value of the shareholders' equity, from the cash the firm can pay its shareholders and lenders (FCFF): 117.34M USD
Fifteen years of free cash flow to the firm (FCFF), each brought to today at the WACC, plus the invested capital at year 15 brought to today, less the net debt today (or plus the net cash).
①Present Value of the 15 Years of FCFF85.74M USD
+②Invested Capital at Year 15, Today21.54M USD
+③Net Cash Today10.06M USD
=Value117.34M USD
FCFF: the NOPAT left for the shareholders and the lenders once the business reinvests what next year's growth needsReinvestment: the part of the year's NOPAT put back into the business to grow the next year; below zero, capital the business releasesPresent value of the FCFFColoured bars show the FCFF, grey bars the reinvestment. With a positive reinvestment the two stacked are the year's NOPAT; with a negative one the grey is below zero, capital the business releases, and the NOPAT is the FCFF plus that negative amount. Shaded, years 6 to 10: the growth rising to its long-run rate and the ROIC on new investment falling to the WACC. Axes linear.

①Present Value of the 15 Years of FCFF

85.74M USD

②Invested Capital at Year 15, Today

21.54M USD

③Net Cash Today

10.06M USD

Market value

Market Cap265.44M USD

The price on the date above times the shares.

Value vs market

Margin of Safety-126.2%

1 minus the market cap as a share of the value.

The Rates and the Capital the Values Read

The WACC and the cost of equity each value is discounted at, the book value and the net debt each starts from, and the seven quality metrics, from the same run.

WACC: 6.48%
Cost of Equity =Risk-Free Rate 4.50%+Beta 0.34×Market Risk Premium 6.00%= 6.56%

The yearly return the shareholders require for the risk they carry; it is the rate that brings their future cash to today.

Tax Rate for WACC =Tax Provision 2.44M USDPretax Income 11.56M USD= 21.10%

The tax the interest saves.

Interest Expense =EBIT 11.91M USD−Pretax Income 11.56M USD= 355.70K USD

The interest the company paid: EBIT is the profit before tax plus the interest.

Cost of Debt =Interest Expense 355.70K USDTotal Debt 7.85M USD×(1 − Tax Rate for WACC 21.10%)= 3.57%

What the lenders are paid a year after the tax the interest saves.

Debt Weight =Total Debt 7.85M USDMarket Cap + Total Debt 265.44M USD + 7.85M USD= 2.87%

The part of the capital the lenders put in, at market value.

WACC =Equity Weight 97.13%×Cost of Equity 6.56%+Debt Weight 2.87%×Cost of Debt 3.57%= 6.48%

Weighted average cost of capital: the yearly return the shareholders and the lenders together require, weighted by what each puts in; the rate that brings the firm's future cash to today.

Book value and net debt today
Both from the balance sheet of the newest quarter, 2025-12-31.

Total Assets 61.25M USD − Total Liabilities 16.02M USD = Book Value Today 45.23M USD

Total Debt 7.85M USD − Cash and Short-Term Investments 17.91M USD = Net Debt Today -10.06M USD

The book value is what Profit starts from and what stands when a projection is not made; the book value plus the net debt is what FCFF starts from; the net debt comes off Greenwald's and FCFF's values before the shareholders.

Quality metrics
Read beside the value, never a condition for it: every company is valued, and a filter in the list is the reader's choice.
MetricFrom
Share dilutionShares Today ÷ Shares Two Years Back − 11.1%at most 5%passes47,850,043 / 47,309,993
Accrual quality(Operating Cash Flow − Net Income) ÷ Total Assets8.2%at least -10.0%passes(14.17M USD − 9.12M USD) ÷ 61.25M USD
Price to bookMarket Cap ÷ Book Value Today5.87×at most 3×does not pass265.44M USD ÷ 45.23M USD
Operating marginOperating Income ÷ Revenue21.0%above 10.0%passes13.40M USD ÷ 63.81M USD
Revenue growthRevenue ÷ Revenue a Year Before − 120.2%above 10.0%passes63.81M USD / 53.08M USD
Net cash(Cash − Total Debt) ÷ Market Cap0.6%above -30%passes(9.52M USD − 7.85M USD) ÷ 265.44M USD
Operating efficiencyOperating Income ÷ Gross Profit26.0%above 25.0%passes13.40M USD ÷ 51.44M USD

Market Data

The provider's ratios and the analysts' consensus beside the argument; none of them enters a value.

Share price

412.86 GBp

Enterprise value

186.08M GBP

the provider's own figure

EV / EBITDA

16.23×

Price / book

5.87×

the provider's book

Price / earnings

25.78×

Return on equity

24.2%

the provider's figure, not this page's

Profit margin

15.9%

Revenue growth

13.6%

Analyst target, mean

475.66 GBp

Analysts

6

opinions in the consensus

Financial Statements

The annual lines the screener holds, year by year, in USD at each period's rate; the figures this valuation read are in its calculation above.

Income statement (USD)2022202320242025

Revenue

37.80M45.47M53.08M63.81M

Gross profit

30.29M35.25M42.50M51.44M

Operating income

2.12M6.67M8.84M13.40M

EBITDA

operating income before depreciation and amortisation

8.46M9.90M12.67M15.76M

Pretax income

1.89M6.46M8.96M11.56M

Net income

1.20M5.63M8.21M9.12M

Normalized income

net income without one-off items, as the data provider prints it; Profit's line when printed

1.20M5.63M8.21M10.59M

R&D

————
Balance sheet, year end (USD)2022202320242025

Total assets

48.19M52.24M55.83M62.26M

Total liabilities

12.13M13.49M14.81M16.95M

Shareholders' equity

the equity the parent's shareholders own, as printed, without minority interest; the book value the values read is total assets less total liabilities, in Book Value and Net Debt above

36.05M38.74M41.03M45.31M

Total debt

7.04M6.54M7.42M8.07M

Cash and equivalents

10.79M8.98M7.77M11.87M

Net PP&E

fixed assets after depreciation

10.15M9.88M11.27M12.34M

Working capital

current assets less current liabilities

19.07M20.93M22.94M25.97M
Cash flow (USD)2022202320242025

Operating cash flow

6.74M10.72M13.78M14.17M

Capital expenditure

paid out, so below zero

-1.46M-3.06M-2.76M-2.72M

Depreciation and amortisation

3.29M3.22M3.43M3.85M

Free cash flow

operating cash flow plus capital expenditure

5.28M7.66M11.02M11.45M